

Jin Li

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/250098/jin-li-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

4,563
citations

33
h-index

64
g-index

205
ext. papers

5,765
ext. citations

4.6
avg, IF

5.38
L-index

#	Paper	IF	Citations
189	Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 281-281	2.2	
188	Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.. <i>Cancer Immunology, Immunotherapy</i> , 2022 , 1	7.4	2
187	Progressive resistance exercise training to prevent lower-limb lymphedema after cervical cancer surgery: A feasibility study.. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022 , 9, 32-38	2.2	0
186	Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs.. <i>Cancer Cell</i> , 2022 , 40, 233-235	24.3	0
185	mPEG-PDLLA Micelles Potentiate Docetaxel for Intraperitoneal Chemotherapy in Ovarian Cancer Peritoneal Metastasis.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 861938	5.6	0
184	Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature.. <i>Frontiers in Oncology</i> , 2021 , 11, 792003	5.3	0
183	Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021 , 53, 547-557	2.8	2
182	A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDX). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	1
181	Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial. <i>Future Oncology</i> , 2021 , 17, 1339-1350	3.6	0
180	A phase I study of a TGF- β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3098-3098	2.2	0
179	Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2566-2566	2.2	3
178	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial. <i>Future Oncology</i> , 2021 , 17, 1923-1931	3.6	0
177	Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2514-2514	2.2	1
176	FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4010-4010	2.2	10
175	Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16037-e16037	2.2	
174	A phase Ib study of the PI3K inhibitor liperlisib in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3099-3099	2.2	
173	Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16034-e16034	2.2	

172	Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study. <i>BioDrugs</i> , 2021 , 35, 445-458	7.9	1
171	WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3106-3106	2.2	
170	Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703). <i>Oncologist</i> , 2021 , 26, e1693-e1703	5.7	7
169	UHRF1 regulates alternative splicing by interacting with splicing factors and U snRNAs in a H3R2me involved manner. <i>Human Molecular Genetics</i> , 2021 , 30, 2110-2122	5.6	0
168	Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies. <i>Cancer Science</i> , 2021 , 112, 962-969	6.9	10
167	CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS255-TPS255	2.2	1
166	Prevalence of psychological disorders in the COVID-19 epidemic in China: A real world cross-sectional study. <i>Journal of Affective Disorders</i> , 2021 , 281, 312-320	6.6	18
165	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021 , 41, 747-795	9.4	36
164	Mesothelial cells are not a source of adipocytes in mice. <i>Cell Reports</i> , 2021 , 36, 109388	10.6	6
163	Neurotensin is an anti-thermogenic peptide produced by lymphatic endothelial cells. <i>Cell Metabolism</i> , 2021 , 33, 1449-1465.e6	24.6	12
162	Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021 , 14, 4439-4450	4.4	1
161	Ultrasound-guided percutaneous transluminal angioplasty for the treatment of cephalic arch stenosis in hemodialysis arteriovenous fistulas. <i>Seminars in Dialysis</i> , 2021 ,	2.5	
160	An inhibitor-mediated beta-cell dedifferentiation model reveals distinct roles for FoxO1 in glucagon repression and insulin maturation. <i>Molecular Metabolism</i> , 2021 , 54, 101329	8.8	0
159	Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 160-160	2.2	33
158	Modeling hepatoblastoma development with human fetal liver organoids reveals YAP1 activation is sufficient for tumorigenesis. <i>Protein and Cell</i> , 2021 , 1	7.2	11
157	Reproductive and obstetric outcomes after abdominal radical trachelectomy (ART) for patients with early-stage cervical cancers in Fudan, China. <i>Gynecologic Oncology</i> , 2020 , 157, 418-422	4.9	12
156	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020 , 46, 955-966	3.6	7
155	Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3638-3638	2.2	1

154	Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+ line metastatic colorectal carcinoma (mCRC) phase III trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16001-e16001	2.3	1
153	First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16126-e16126	2.2	1
152	First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS1101-TPS1101	2.2	7
151	Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020 , 32, 403-407	3.8	2
150	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1307-1316	4	4
149	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. <i>Cancer Biology and Therapy</i> , 2020 , 21, 891-898	4.6	7
148	Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. <i>Chinese Clinical Oncology</i> , 2020 , 9, 68	2.3	2
147	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase III FRESCO Trial. <i>Advances in Therapy</i> , 2020 , 37, 4585-4598	4.1	1
146	DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns. <i>Drug Discovery Today</i> , 2020 , 25, 951-955	8.8	3
145	Histone-Related Genes Are Hypermethylated in Lung Cancer and Hypermethylated Could Serve as a Pan-Cancer Biomarker. <i>Cancer Research</i> , 2019 , 79, 6101-6112	10.1	15
144	Guide Positioning Sequencing identifies aberrant DNA methylation patterns that alter cell identity and tumor-immune surveillance networks. <i>Genome Research</i> , 2019 , 29, 270-280	9.7	14
143	Reply to C. Kersten et al and D.A. Parikh et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1592-1593	2.2	0
142	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <i>Cancer Communications</i> , 2019 , 39, 10	9.4	199
141	An alternatively transcribed variant negatively regulates JAK-STAT signaling. <i>EMBO Reports</i> , 2019 , 20,	6.5	10
140	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition). <i>Journal of Hematology and Oncology</i> , 2019 , 12, 16	22.4	33
139	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. <i>Cancer Communications</i> , 2019 , 39, 38	9.4	10
138	A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2526-2526	2.2	1
137	Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4025-4025	2.2	1

136	Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4054-4054	2.2	1
135	Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019 , 31, 423-425	3.8	4
134	Sequencing of different targeted therapies in management of KRAS wild-type metastatic colorectal cancer: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 679-679	2.2	
133	Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESKO trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15012-e15012	2.2	1
132	Protocadherin-8 promotes invasion and metastasis via laminin subunit α in gastric cancer. <i>Cancer Science</i> , 2018 , 109, 732-740	6.9	17
131	Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. <i>Drug Discovery Today</i> , 2018 , 23, 1175-1182	8.8	116
130	Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays. <i>Antiviral Research</i> , 2018 , 152, 45-52	10.8	13
129	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. <i>Medicinal Research Reviews</i> , 2018 , 38, 325-376	14.4	29
128	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. <i>Future Oncology</i> , 2018 , 14, 2031-2044	3.6	11
127	Influence of hypoxia-related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF. <i>Oncology Letters</i> , 2018 , 15, 1334-1342	2.6	1
126	Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 \pm cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3521-3521	2.2	3
125	Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESKO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3537-3537	2.2	1
124	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESKO trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3544-3544	2.2	1
123	Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4039-4039	2.2	1
122	Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16019-e16019	2.2	1
121	Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 35-35	2.2	3
120	Effect of region and hospital attribute on outcome of gastric patients treated with apatinib: Data from post-marketing phase IV study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 40-40	2.2	
119	Apatinib as third-line or beyond therapy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction: An open-label, multicenter, post-marketing phase IV study (Ahead-G201).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 103-103	2.2	

118	Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 73-73	2.2	
117	Safety and efficacy of apatinib in elderly patients with advanced or metastatic gastric cancer in the post-marketing phase IV study: Subgroup analysis by age (Ahead-G201).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 126-126	2.2	
116	Prognostic factors for survival in apatinib-treated gastric cancer: Results from a post-marketing phase IV study (Ahead-G201).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 19-19	2.2	
115	Comparisons between intestinal and diffuse gastric cancer in response to apatinib: Data from post-marketing phase IV study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 36-36	2.2	
114	Effects of apatinib dose interruptions on safety and efficacy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 142-142	2.2	
113	Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16022-e16022	2.2	
112	BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16027-e16027	2.2	
111	Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16021-e16021	2.2	
110	Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16020-e16020	2.2	
109	Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16026-e16026	2.2	
108	Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16028-e16028	2.2	
107	Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3031-3039	2.2	89
106	Reply to P. Di Nardo et al and R. Sun et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1380-1381	2.2	1
105	The safety of apatinib for the treatment of gastric cancer. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 1145-1150	4.150	30
104	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2486-2496	27.4	99
103	MicroRNAs activate gene transcription epigenetically as an enhancer trigger. <i>RNA Biology</i> , 2017 , 14, 1326-1334	4.163	
102	An integrated analysis of cancer genes in clear cell renal cell carcinoma. <i>Future Oncology</i> , 2017 , 13, 715-725	3.25	5
101	Label-free Proteomic Analysis of Exosomes Derived from Inducible Hepatitis B Virus-Replicating HepAD38 Cell Line. <i>Molecular and Cellular Proteomics</i> , 2017 , 16, S144-S160	7.6	33

100	Prognostic significance and functional implication of immune activating receptor NKG2D in gastric cancer. <i>Biochemical and Biophysical Research Communications</i> , 2017 , 487, 619-624	3.4	7
99	Analysis of expression of transcription factors in early human retina. <i>International Journal of Developmental Neuroscience</i> , 2017 , 60, 94-102	2.7	4
98	A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. <i>BMC Cancer</i> , 2017 , 17, 188	4.8	7
97	DKK4 enhances resistance to chemotherapeutics 5-Fu and YN968D1 in colorectal cancer cells. <i>Oncology Letters</i> , 2017 , 13, 587-592	2.6	9
96	The current status of treatment for colorectal cancer in China: A systematic review. <i>Medicine (United States)</i> , 2017 , 96, e8242	1.8	59
95	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. <i>Chinese Journal of Cancer</i> , 2017 , 36, 97		14
94	Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. <i>Cancer Science</i> , 2017 , 108, 2045-2051	6.9	7
93	Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. <i>International Journal of Cancer</i> , 2017 , 141, 2093-2102	7.5	11
92	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 22	22.4	35
91	Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2017 , 22, 638-e56	5.7	3
90	Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 153	22.4	53
89	A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3508-3508	2.2	4
88	A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 128-128	2.2	4
87	Impact of primary tumor location (TL) on outcomes of first-line (1L) FOLFOX-4 (F) ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 683-683	2.2	3
86	Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. <i>Oncotarget</i> , 2017 , 8, 37826-37834	3.3	10
85	Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases. <i>Oncotarget</i> , 2017 , 8, 51840-51847	3.3	25
84	Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. <i>Oncotarget</i> , 2017 , 8, 35783-35791	3.3	21
83	Menstrual pattern after abdominal radical trachelectomy. <i>Oncotarget</i> , 2017 , 8, 53146-53153	3.3	10

82	A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3513-3513	2.2	
81	Comparison of efficacy and safety of first-line palliative chemotherapy with TX and XELOX regimens in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4070-4070	2.2	
80	Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4052-4052	2.2	
79	Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. <i>Molecular Oncology</i> , 2016 , 10, 1551-1558	7.9	38
78	A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 259-69	3.5	32
77	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. <i>Chinese Journal of Cancer</i> , 2016 , 35, 13		9
76	MBD3L2 promotes Tet2 enzymatic activity for mediating 5-methylcytosine oxidation. <i>Journal of Cell Science</i> , 2016 , 129, 1059-71	5.3	14
75	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1448-54	2.2	566
74	The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 1603-10	12.9	20
73	Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy. <i>Tumor Biology</i> , 2016 , 37, 1753-62	2.9	8
72	Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 672-672	2.2	9
71	Associations of genotypes and haplotypes of IL-17 with risk of gastric cancer in an eastern Chinese population. <i>Oncotarget</i> , 2016 , 7, 82384-82395	3.3	7
70	Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. <i>Oncotarget</i> , 2016 , 7, 9815-31	3.3	72
69	Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. <i>Oncotarget</i> , 2016 , 7, 10332-44	3.3	38
68	Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer. <i>Oncotarget</i> , 2016 , 7, 22733-45	3.3	10
67	Genetic variant of miR-146a rs2910164 C>G and gastric cancer susceptibility. <i>Oncotarget</i> , 2016 , 7, 34316-21	3.3	13
66	Abdominal scar characteristics as a predictor of cervical stenosis after abdominal radical trachelectomy. <i>Oncotarget</i> , 2016 , 7, 37755-37761	3.3	5
65	Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofactory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 507-507	2.2	

64	Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 519-519	2.2	3
63	Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3538-3538	2.2	
62	Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15050-e15050	2.2	
61	PSCA polymorphisms and gastric cancer susceptibility in an eastern Chinese population. <i>Oncotarget</i> , 2016 , 7, 9420-8	3.3	13
60	MicroRNA-421 regulated by HIF-1 α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. <i>Oncotarget</i> , 2016 , 7, 24466-82	3.3	86
59	Associations of potentially functional variants in IL-6, JAKs and STAT3 with gastric cancer risk in an eastern Chinese population. <i>Oncotarget</i> , 2016 , 7, 28112-23	3.3	15
58	Genetic variant rs4072037 of MUC1 and gastric cancer risk in an Eastern Chinese population. <i>Oncotarget</i> , 2016 , 7, 15930-6	3.3	6
57	Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. <i>Gastroenterology Research and Practice</i> , 2016 , 2016, 4105615	2	27
56	Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery. <i>Current Treatment Options in Oncology</i> , 2016 , 17, 44	5.4	21
55	The Survival Rate and Surgical Morbidity of Abdominal Radical Trachelectomy Versus Abdominal Radical Hysterectomy for Stage IB1 Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2953-8	3.1	16
54	Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2016 , 68, 51-59	7.5	42
53	Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3823-3824	2.2	
52	Incidence, risk factors and treatment of cervical stenosis after radical trachelectomy: A systematic review. <i>European Journal of Cancer</i> , 2015 , 51, 1751-9	7.5	39
51	Effects of IGF2BP2, KCNQ1 and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen. <i>Pharmacogenomics</i> , 2015 , 16, 959-70	2.6	20
50	A new method of surgical margin assuring for abdominal radical trachelectomy in frozen section. <i>European Journal of Cancer</i> , 2015 , 51, 734-41	7.5	6
49	UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop. <i>Journal of Pathology</i> , 2015 , 235, 656-67	9.4	15
48	miR-449b rs10061133 and miR-4293 rs12220909 polymorphisms are associated with decreased esophageal squamous cell carcinoma in a Chinese population. <i>Tumor Biology</i> , 2015 , 36, 8789-95	2.9	27
47	Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection. <i>Journal of Immunology</i> , 2015 , 195, 4873-83	5.3	60

46	Genetic variant of PRKAA1 and gastric cancer risk in an eastern Chinese population. <i>Oncotarget</i> , 2015 , 6, 42661-6	3.3	17
45	MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer. <i>Oncotarget</i> , 2015 , 6, 25418-28	3.3	43
44	Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men. <i>BioMed Research International</i> , 2015 , 2015, 481621	3	16
43	Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. <i>Oncotarget</i> , 2015 , 6, 40519-34	3.3	14
42	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 619-29	21.7	428
41	Cognitive frailty, a novel target for the prevention of elderly dependency. <i>Ageing Research Reviews</i> , 2015 , 20, 1-10	12	140
40	A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 513-513	2.2	8
39	A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 667-667	2.2	1
38	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 697-697	2.2	1
37	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 740-740	2.2	7
36	Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. <i>Oncotarget</i> , 2015 , 6, 20093-22	3.3	40
35	miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. <i>Oncotarget</i> , 2015 , 6, 24448-62	3.3	61
34	Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen. <i>Oncotarget</i> , 2015 , 6, 39018-27	3.3	11
33	Effects of IGF2BP2, KCNQ1, and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 64-64	2.2	
32	Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 133-133	2.2	
31	Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 705-705	2.2	
30	Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3560-3560	2.2	
29	Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 145-55	3.8	14

28	Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. <i>PLoS ONE</i> , 2014 , 9, e100055	3.7	54
27	Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy. <i>PLoS ONE</i> , 2014 , 9, e116027	3.7	18
26	MUC1 gene polymorphism rs4072037 and susceptibility to gastric cancer: a meta-analysis. <i>SpringerPlus</i> , 2014 , 3, 599		12
25	Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2014 , 14, 986	4.8	5
24	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 4559-73	12.9	53
23	On what scale does it benefit the patients if uterine arteries were preserved during ART?. <i>Gynecologic Oncology</i> , 2014 , 134, 154-9	4.9	28
22	A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3548-3548	2.2	3
21	The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway. <i>PLoS ONE</i> , 2014 , 9, e85116	3.7	32
20	Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e105524	3.7	38
19	S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil. <i>International Journal of Clinical and Experimental Pathology</i> , 2014 , 7, 3293-8	1.4	
18	S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil. <i>International Journal of Clinical and Experimental Pathology</i> , 2014 , 7, 4274-9	1.4	4
17	LRP5 polymorphism-A potential predictor of the clinical outcome in advanced gastric cancer patients treated with EOF regimen. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014 , 26, 478-85	3.8	2
16	Genetic polymorphism of the phospholipase C epsilon 1 gene and risk of gastric cancer. <i>Chinese Medical Journal</i> , 2014 , 127, 2511-7	2.9	8
15	Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3219-23 ²	23.2	367
14	Abdominal radical trachelectomy: Is it safe for IB1 cervical cancer with tumors \geq 2 cm?. <i>Gynecologic Oncology</i> , 2013 , 131, 87-92	4.9	44
13	Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 57-63	3.5	1
12	Efficacy and tolerability of bevacizumab (BEV) plus capecitabine and cisplatin (XP) in Chinese patients (pts) with locally advanced or metastatic gastric/gastroesophageal junction cancer (AGC): Results from the AVATAR study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 73-73	2.2	3
11	Radical abdominal trachelectomy for cervical malignancies: surgical, oncological and fertility outcomes in 62 patients. <i>Gynecologic Oncology</i> , 2011 , 121, 565-70	4.9	64

10	Immunohistochemical study of nuclear factor- κ B activity in colorectal cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2011 , 10, 406-409		1
9	Effects of variant rs346473 in ARHGAP24 gene on disease progression of HBV infection in Han Chinese population. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2011 , 31, 482		2
8	Associations of HLA-DP variants with hepatitis B virus infection in southern and northern Han Chinese populations: a multicenter case-control study. <i>PLoS ONE</i> , 2011 , 6, e24221	3.7	47
7	BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. <i>Molecular Cancer</i> , 2010 , 9, 40	42.1	70
6	Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. <i>BMC Cancer</i> , 2010 , 10, 529	4.8	179
5	STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25,014 subjects. <i>Breast Cancer Research and Treatment</i> , 2009 , 118, 599-603	4.4	7
4	Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2008 , 19, 745-8	2.4	1
3	Primary non-Hodgkin's lymphoma of the breast: eight-year follow-up experience. <i>International Journal of Hematology</i> , 2008 , 87, 491-497	2.3	32
2	Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. <i>Gynecologic Oncology</i> , 2007 , 105, 769-75	4.9	21
1	Phase II study of mitomycin C and cisplatin in heavily pretreated advanced breast cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2006 , 5, 442-445		1